ArticleHeliyon2024
Factors associated with time to death among HIV/TB co-infected patients on ART in Dire Dawa, Ethiopia: A retrospective study.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predictive Factors Associated With Multidrug-Resistant Tuberculosis Among Tuberculosis Patients in Southwest Ethiopia: An Unmatched Case-Control Study.Health science reports · 2025Article
- Survival time and influencing factors among people living with HIV in Guilin City, Guangxi, China: a retrospective cohort study (1996-2022).Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculosis is one of the leading causes of death, especially for people living with HIV. However, little is known about the time to death of HIV/TB co-infected patients and associated factors in the study area. This study focused on identifying factors associated with time to death among HIV/TB co-infected patients under antiretroviral therapy in Ethiopia. Methods: From January 2008 to January 2023, a hospital-based retrospective study was conducted on 434 HIV/TB co-infected patients attending the ART clinic at Dilchora Referral Hospital in Dire Dawa, Ethiopia. The medical records were reviewed using a structured data extraction tool. Data were entered with Epi Info version 7 and analyzed with Stata version 17. The Kaplan-Meier survival curve was used along with log-rank tests to estimate and compare survival times. Bi-variable and multivariable Cox regression were performed to identify factors associated with time to mortality in HIV/TB co-infected patients. The adjusted hazard ratio with its 95 % confidence interval was used to estimate the strength of the association and a P-value of 0.05 was considered statistically significant. Results: The study included 434 HIV/TB co-infected patients. The overall median survival time was 144 months (95 % CI: [132, 156]). One hundred thirty-four (30.88 %) deaths were observed during follow-up, resulting in an all-cause mortality rate of 5.1 (95 % CI: [4.29, 6.02]) per 1000 person-months of study follow-up. The independent determinants of mortality were underweight BMI (AHR: 4.52; 95 % CI: [1.30, 15.67]), poor ART adherence (AHR: 1.60; 95 % CI: [1.03, 2.50]), advanced WHO clinical stage (AHR: 1.69; 95 % CI: [1.1, 2.62]), bedridden functional status (AHR: 1.63; 95 % CI: [1.04, 2.57]), initial ART regimen (AHR: 2.68; 95 % CI: [1.74, 4.12]), and smoking status (AHR: 1.48; 95 % CI: [1.01, 2.16]). Conclusion: The mortality rate of HIV/TB co-infected patients in this study was very high. While implementing target improvements in the National Tuberculosis and HIV Program, healthcare providers and policymakers should give higher priority to these risk factors identified in the present study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.